ProfileGDS5678 / 1426535_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 73% 70% 74% 77% 62% 70% 74% 79% 73% 73% 72% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7399273
GSM967853U87-EV human glioblastoma xenograft - Control 24.6756173
GSM967854U87-EV human glioblastoma xenograft - Control 34.3269470
GSM967855U87-EV human glioblastoma xenograft - Control 45.0149474
GSM967856U87-EV human glioblastoma xenograft - Control 55.2027277
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8072262
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3586170
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7780174
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5838279
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7481473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7279473
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6053772
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8016774
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7791574